Teriparatide
Research News and Information

Saturday, March 20, 2010

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.

5 Oct 2009 CONTEXT: National public insurance for drugs is often based on evidence of comparative effectiveness and cost-effectiveness. This study describes how that evidence has been used across 3 jurisdictions (Australia, Canada, and Britain) that have been ... Read more...

Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

30 Jul 2009 We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 microg/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis. Evaluable biopsies ... Read more...

Corticosteroids: no drug prevention of fractures needed.

30 Jul 2009 Long-term corticosteroid therapy increases the risk of fractures, which depends on the dose and duration of treatment. No drugs have been demonstrated to reduce the incidence of symptomatic fractures in this setting. It is better to keep the dose ... Read more...

Latest indexed articles for 'Teriparatide'

These are the very latest articles for this heading:

• Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. 5 Oct 2009
• Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. 30 Jul 2009
• Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. 30 Jul 2009
• Corticosteroids: no drug prevention of fractures needed. 30 Jul 2009
• Teriparatide: new indication. During corticosteroid therapy: no fewer clinical fractures. Unnecessarily inconvenient. 30 Jul 2009
• Fracture prevention in men. 26 Jul 2009
• Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. 5 Jul 2009
• Clinical update on teriparatide. 29 Jun 2009
• [Bone remodeling: new therapeutic approaches] 8 Jun 2009
• Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. 30 May 2009
• Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. 30 May 2009
• Pharmacotherapeutic management of osteoprosis and osteopenia. 30 May 2009
• Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. 30 May 2009
• Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. 10 May 2009
• [Drugs under development for osteoporosis ] 29 Apr 2009
• Effects of teriparatide retreatment in osteoporotic men and women. 26 Apr 2009
• No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. 30 Mar 2009
• Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. 30 Mar 2009
• Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). 30 Mar 2009
• [Intermittent low-dose administration of recombinant human parathyroid hormone (1-34) promotes the expression of Runx2 during early stage of fracture healing] 22 Mar 2009

See a longer list of these articles.

Technical information about 'Teriparatide'

Definition: A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

Registry Number: 52232-67-4

Descriptor UI: D019379

Alternative terms: Teriparatide; hPTH (1-34); Human Parathyroid Hormone (1-34); Parathar; Aventis Brand of Teriparatide; Teriparatide Aventis Brand; Teriparatide Acetate; Forteo; Lilly Brand of Teriparatide; Teriparatide Lilly Brand;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Bone Density Conservation Agents;

Tree Number: D06.472.699.590.850; D12.644.548.587.850;

Online Note: use TERIPARATIDE (NM) to search PARATHYROID HORMONE PEPTIDE (1-34) 1978-96

History Note: 97; was PARATHYROID HORMONE PEPTIDE (1-34) (NM) 1978-96